

## Special Issue

# Inflammation and Brain Diseases

### Message from the Guest Editors

Inflammation is the common denominator of several CNS pathologies. It is now well-accepted that inflammatory pathways are involved in the pathogenesis of several neurodegenerative disorders. Clinical observations and experimental findings support a link between inflammation and epilepsy. In the brain, the major players in the inflammatory response are resident cellular elements. Microglia and astrocytes are strongly activated in most neurodegenerative diseases and produce a variety of inflammatory mediators. However, in recent decades, most findings have suggested that inflammation exacerbates the pathological manifestation of CNS diseases. This evidence has framed inflammation as a common target for a broad range of CNS diseases. Thus, anti-inflammatory agents could potentially be effective for different pathologies. Approved anti-inflammatory drugs, as well as innovative, multifunctional, and/or hybrid molecules, are fundamental tools both in elucidating pathological pathways of brain diseases and in mitigating disease progression. This SI aims to provide an overview of approved drugs exploited in brain diseases and to highlight state-of-the-art new compounds under study.

---

### Guest Editors

Dr. Chiara Cerri

Dr. Lidia Ciccone

Dr. Susanna Nencetti

---

### Deadline for manuscript submissions

closed (15 October 2023)



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

**Impact Factor 4.3**  
**CiteScore 6.1**  
**Indexed in PubMed**



[mdpi.com/si/145005](https://mdpi.com/si/145005)

*Pharmaceuticals*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.3  
CiteScore 6.1  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Pharmaceutical Science)